Several studies have demonstrated the role of OMT in various musculoskeletal disorders. The largest trial on OMT for patients with LBP with a subpopulation of diabetic patients was called the OSTEOPATHIC trial.
9 It was a randomized, double-blind, sham-controlled 2 × 2 factorial designed study with a sample size of 455. The trial showed a large effect size for OMT in providing significant LBP improvement in patients with high baseline pain severity (RR, 2.04; 95% CI, 1.36-3.05;
P<.001). The trial also found clinically important improvement in back-specific functioning (RR, 1.80; 95% CI, 1.08-3.01;
P=.02), decreased use of prescription medication for LBP (RR, 0.64; 95% CI, 0.36-1.13;
P<.12), and greater patient satisfaction with back care (RR, 1.30; 95% CI, 1.13-1.49;
P<.001). Subgroup results from the OSTEOPATHIC trial also found that severe somatic dysfunction was present significantly more often in patients with DM than in patients without DM.
17 The subgroup of diabetic patients had a clinically relevant reduction not only in LBP but also in TNF-α serum concentration in those who received OMT compared with those who received sham OMT (mean between-group difference, −0.6pg/mL; 95% CI, −12.4 to −0.8pg/mL;
P= .03), suggesting that decreased circulating TNF-α may represent a possible mechanism for OMT effects in patients with diabetes mellitus.
17 TNF-α is a pro-inflammatory cytokine involved in the development of diabetic neuropathy.
18 Although diabetic patients with LBP responded favorably to OMT to reduce their LBP, no long-term follow-up with blood sugar assessments were performed, so the overall effect of the LBP reduction on diabetes was not determined.